Tagged with Hong Kong,

Hong Kong Small markets must inevitably etch out a niche positioning for themselves, and for Hong Kong, its world-class medical infrastructure, world-renowned academics and clinicians as well as high population density make it a strong contender in clinical research.   Hong Kong is an important piece of our global R&D landscape Scott…

Hong Kong Novartis Hong Kong general manager Dorine Leung and oncology head Sian Ng discuss the company’s restructuring, dividing the oncology business unit from the pharmaceutical division. In addition, they share their insights on what makes Hong Kong a destination for world-class clinical trials. Novartis recently underwent a major restructuring with the…

Hong Kong Joyce Wong, managing director for APAC at compliance solutions provider Polaris in Hong Kong, describes the company’s innovative solutions for its clients in the life sciences, the significance of basing its regional headquarters in Hong Kong, and increasing compliance across the industry. It is very atypical for a senior executive…

Hong Kong In 2017, Hong Kong fended off perennial competitors, life sciences hubs and innovation powerhouses, Switzerland and Singapore, to rank first in the International Institute for Management Development (IMD)’s World Competitiveness Rankings, clear evidence that conditions are ripe in Hong Kong to develop the first biotech unicorn – a start-up company…

Hong Kong Johnny Tse, general manager of Roche Diagnostics Hong Kong, talks about the past seven years managing the affiliate, how the company became a market leader, and his aim to position Roche Diagnostic as a solutions provider. Having managed Roche Diagnostics Hong Kong for nearly seven years now, what have been…

Hong Kong Described as the first unicorn [a startup company valued at over USD 1 billion] of Hong Kong, Cirina has recently merged with Grail to further improve detection of cancer at its early stage. Pharmaboardroom sat down with Professor Denis Lo, the man behind Cirina’s technology, to further discuss his groundbreaking…

Hong Kong Charles Ng and Simon Tsang of InvestHK, Hong Kong’s investment promotion agency, discuss the territory’s strengths in the life sciences sector, the potential of the HK industry to grow further, and its regional significance. The Swiss-based International Institute for Management Development (IMD) recently placed Hong Kong at the top of…

Hong Kong Scott Curley, general manager of Astra Zeneca Hong Kong, discusses how his affiliate managed to achieve its successful product launch track record; shares his insights on the key specificities of Hong Kong and further explains why it is an important market for Astra Zeneca’s global R&D. Having previously worked extensively…

Hong Kong Professor Cheng, managing director of the Hong Kong Institute of Biotechnology, introduces the organization’s mission to improve development of biotechnology and traditional Chinese medicine sectors as well as the main challenges ahead. What is the mandate of the Hong Kong Institute of Biotechnology (HKIB)? “Our mission statement was – and…

Hong Kong Alexandre de Muralt, the man behind Merck’s operations in Hong Kong and Taiwan discusses the nuances of these two local markets. In addition, he shares his insights on how Merck’s transformation has impacted local affiliates. Can you begin by telling us about Merck’s strategic transformation in recent years? “Founded in…

Hong Kong The Ming Wai Lau Center for Reparative Medicine was established in October 2016 as the first international arm of Karolinska Institute (KI) in over 200 years! What is the Center’s mission? “Hong Kong has been a trading port for centuries, and this is something Hong Kong can continue to leverage…

Hong Kong Hybribio is a very interesting company, being founded in Hong Kong and now headquartered in Guangzhou as one of the leading providers of in-vitro diagnostic (IVD) assays in Greater China with significant international presence as well. Can you tell us more about the company’s positioning today? “We have launched several…